Forensic Technology Market Size, Share & Trends Analysis Report By Product (Polymerase Chain Reaction (PCR), Capillary Electrophoresis, Next-Generation Sequencing (NGS), Rapid DNA Analysis, Automated Liquid Handling Technology, Microarrays, Others), By Applications (Pharmacogenetics, Biodefense & Biosurveillance, Judicial and Law Enforcement, Others), By End Use, By Region, and Segment Forecasts - 2035

Forensic Technology Market Overview

The global forensic technology market size was valued at USD 23982.38 million in 2025 and is projected to grow from USD 27445.43 million in 2026 to USD 41134.24 million by 2035, exhibiting a CAGR of 14.44% during the forecast period.

The Forensic Technology Market in 2026 is being transformed by faster DNA workflows, automated sample preparation, high-throughput genetic analysis, advanced toxicology, digital laboratory management, and increasing adoption of Next-Generation Sequencing (NGS) for difficult biological evidence. Polymerase Chain Reaction (PCR) is estimated to represent approximately 26% of Product Type demand, followed by Capillary Electrophoresis at approximately 20%, Next-Generation Sequencing (NGS) at 17%, Rapid DNA Analysis at 13%, Automated Liquid Handling Technology at 10%, Microarrays at 6%, and Others at approximately 8%. Judicial and Law Enforcement is estimated to account for approximately 54% of Application demand, followed by Pharmacogenetics at 20%, Biodefense & Biosurveillance at 15%, and Others at 11%. DNA databases are expanding rapidly, with major national systems containing more than 25 million profiles and adding more than 1 million samples annually. Rapid DNA systems can now generate forensic-quality profiles in approximately 90 minutes while automated laboratory platforms can process up to 96 samples in less than 90 minutes during selected workflow stages. These improvements are helping laboratories address case backlogs while increasing reproducibility, traceability, contamination control, and throughput.

The United States remains one of the most technologically advanced markets for forensic analysis because more than 200 law-enforcement laboratories participate in interconnected DNA comparison systems, and national databases contain over 25 million DNA profiles. The U.S. National DNA Index included more than 19 million offender profiles, over 6 million arrestee profiles, and more than 1.4 million forensic profiles by late 2025, demonstrating the scale of biological evidence processing. Thermo Fisher Scientific Inc., GE Healthcare, Agilent Technologies, Inc., Forensic Fluids Laboratories, NMS Labs, and NEOGEN CORPORATION provide substantial supplied-company representation from the U.S. Judicial and Law Enforcement applications are estimated to represent approximately 58% of domestic forensic technology demand. The U.S. market is increasingly focused on reducing turnaround times, with Rapid DNA Analysis producing selected profiles in approximately 90 minutes and automated extraction and preparation platforms processing as many as 96 DNA samples within comparable timeframes. Investment is also expanding in NGS, forensic toxicology, advanced mass spectrometry, automated liquid handling, and software-driven interpretation as laboratories seek to process larger evidence volumes without proportionally increasing headcount.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Polymerase Chain Reaction (PCR) is estimated to hold approximately 26% market share because amplification remains central to human identification, forensic DNA profiling, biological evidence screening, and confirmatory workflows.
• Leading Application: Judicial and Law Enforcement is estimated to account for approximately 54% of demand, supported by DNA databases containing more than 25 million profiles in major national systems.
• Leading Region: North America is estimated to hold approximately 39% market share, supported by more than 200 interconnected U.S. law-enforcement laboratories and extensive investment in forensic DNA infrastructure.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 16.8% annually as governments modernize forensic laboratories, DNA databases, toxicology systems, biometric identification, and automated evidence-processing capabilities.
• Technology Trend: Rapid DNA Analysis is gaining adoption because advanced systems can generate forensic-quality DNA profiles in approximately 90 minutes with minimal hands-on processing.
• Market Driver: Growing evidence volumes support automation investment as selected laboratory systems can purify and prepare as many as 96 DNA samples in less than 90 minutes.
• Competitive Landscape: Laboratory expansion remains active, with one major forensic-services operator completing a new approximately 5,000-square-meter facility incorporating DNA recovery, drug analysis, and elemental analysis capabilities.
• Future Outlook: Next-Generation Sequencing (NGS) will gain importance as forensic laboratories move beyond traditional STR analysis toward massively parallel examination of hundreds of genetic markers.

Latest Trends

Rapid DNA Analysis is one of the most important trends shaping the Forensic Technology Market in 2026. Conventional forensic DNA processing can require multiple laboratory stages involving extraction, quantification, amplification, separation, interpretation, technical review, and database comparison. Rapid DNA systems integrate several of these functions into closed automated platforms capable of generating profiles in approximately 90 minutes from selected samples while requiring around 1 minute of direct hands-on operation. Research published during 2026 demonstrated that an additional approximately 12-minute pre-extraction step can improve DNA recovery from more challenging evidence before Rapid DNA processing. These improvements broaden potential use beyond high-quality reference samples toward selected crime-scene materials, human remains, disaster identification, human trafficking investigations, and time-sensitive law-enforcement scenarios. Rapid DNA Analysis currently represents an estimated 13% of Product Type demand but is expected to grow faster than the overall market through 2035 as performance improves and laboratory validation expands.

Next-Generation Sequencing (NGS) and advanced forensic toxicology represent another major technology shift. Conventional Capillary Electrophoresis remains important for established STR workflows, but NGS enables laboratories to analyze substantially larger collections of genetic markers simultaneously, including autosomal STRs, Y-STRs, X-STRs, SNPs, mitochondrial DNA targets, and ancestry-related markers depending on validated workflows. This capability is particularly valuable when DNA is degraded, mixed, limited, or insufficient for standard testing. Forensic toxicology is undergoing a similar transition toward larger compound libraries and higher-resolution mass spectrometry. Modern analytical databases can contain more than 2,800 target compounds, while accurate-mass libraries can incorporate more than 9,000 compounds and thousands of MS/MS spectra. Laboratories are therefore moving from narrow targeted testing toward broader screening capable of identifying synthetic drugs, metabolites, poisons, pharmaceuticals, and unknown compounds from increasingly complex evidence.

Market Dynamics

Driver

""Growing forensic caseloads are accelerating adoption of faster and more automated analytical workflows.""

The strongest driver of the Forensic Technology Market is the increasing quantity of biological and chemical evidence entering laboratories. Major DNA databases now contain more than 25 million profiles and receive over 1 million additional DNA samples annually. In the United States, forensic DNA infrastructure has supported more than 750,000 investigations through database-assisted matches and investigative leads. This scale places substantial pressure on laboratories to increase throughput without compromising quality assurance. Polymerase Chain Reaction (PCR), representing approximately 26% of Product Type demand, remains essential because small quantities of biological material must often be amplified before interpretation. Automated extraction, liquid handling, and Rapid DNA Analysis are increasingly layered around PCR workflows to reduce manual pipetting and improve repeatability.

Law-enforcement demand is particularly influential because Judicial and Law Enforcement represents approximately 54% of Application activity. A national laboratory system processing more than 1 million additional DNA samples annually must handle an average exceeding 2,700 new samples each day before considering existing crime-scene cases, quality checks, reanalysis, and database administration. Automated liquid-handling platforms capable of processing 96 samples per batch therefore offer substantial productivity improvements. When 10 such batches are completed, approximately 960 samples can move through selected preparation stages with limited manual intervention. This scalability makes automation increasingly necessary rather than optional for high-volume forensic laboratories.

Restraint

""Validation requirements and high analytical complexity can slow deployment of emerging forensic technologies.""

A major restraint is the rigorous validation required before new forensic technologies can support criminal investigations or judicial proceedings. A laboratory cannot simply replace a validated Capillary Electrophoresis workflow with Next-Generation Sequencing (NGS) because the new method must demonstrate sensitivity, specificity, reproducibility, precision, contamination control, mixture interpretation, and quality assurance. Validation may involve hundreds or thousands of test samples before operational deployment. Laboratory personnel must also complete competency assessments, standard operating procedures, instrument maintenance protocols, and interpretation training. Capillary Electrophoresis therefore retains approximately 20% of Product Type demand because its STR workflows are well established and widely understood by forensic practitioners and courts.

Capital intensity also restrains adoption. A modern forensic laboratory may require PCR instruments, genetic analyzers, sequencers, automated extraction platforms, liquid handlers, chromatography equipment, mass spectrometers, microscopes, evidence-management systems, and secure data infrastructure. Advanced toxicology laboratories may maintain compound libraries exceeding 2,800 analytes and multiple analytical methods for blood, urine, oral fluids, tissues, powders, and unknown substances. Smaller jurisdictions processing fewer than 1,000 cases annually may find it difficult to justify every advanced technology internally. Outsourcing to specialized laboratories therefore remains important, particularly for NGS, advanced toxicology, unusual trace evidence, and low-volume specialized tests.

Opportunity

""NGS and automated sample processing are creating significant opportunities to resolve complex and previously inconclusive evidence.""

The strongest opportunity is applying Next-Generation Sequencing (NGS) to samples that generate limited information using conventional methods. NGS represents approximately 17% of Product Type demand but is projected to increase its share through 2035. Whereas conventional forensic STR testing evaluates a comparatively limited number of loci, massively parallel sequencing can evaluate hundreds of markers within one analytical workflow. This can increase information recovery from degraded remains, mixed samples, missing-person investigations, and historical evidence. NGS also creates opportunities within Biodefense & Biosurveillance, which represents approximately 15% of Application demand, because sequencing can help characterize biological organisms and genomic variation during surveillance or investigation.

Automation creates an equally significant opportunity. Automated Liquid Handling Technology currently accounts for approximately 10% of Product Type demand but directly addresses laboratory capacity constraints. Modern platforms can process up to 96 DNA samples in less than 90 minutes during selected purification, quantification, and amplification preparation steps. A laboratory operating 4 automated batches per workday could therefore prepare hundreds of samples with less hands-on pipetting. Automation also improves chain-of-custody traceability because barcodes, instrument logs, robotic movement, and laboratory information systems can document each processing step. This combination of throughput and traceability makes automated liquid handling increasingly attractive for high-volume judicial laboratories.

Challenge

""Evidence complexity and data interpretation continue to test laboratory capacity and specialist expertise.""

The central technical challenge is that forensic evidence frequently contains complex mixtures, degradation, contamination, low DNA concentrations, or multiple unknown compounds. Rapid DNA systems can produce profiles within approximately 90 minutes from appropriate samples, but low-template or mixed evidence may still require conventional laboratory processing. Even a 12-minute pre-extraction enhancement cannot eliminate every limitation associated with difficult crime-scene samples. Laboratories therefore need decision rules determining which evidence is appropriate for Rapid DNA Analysis and which should proceed through full extraction, quantification, amplification, Capillary Electrophoresis, or NGS workflows. Incorrect workflow selection can waste limited sample material and increase turnaround time.

Data interpretation is becoming another major challenge as analytical platforms generate larger datasets. An NGS run can examine hundreds of genetic markers, while forensic mass-spectrometry libraries contain thousands of compounds and spectra. Agilent analytical libraries, for example, support screening across more than 2,800 toxicology-related compounds in one database architecture, illustrating the scale of modern forensic interpretation. Laboratories need trained analysts, validated algorithms, secure storage, quality-control procedures, and defensible interpretation frameworks. Through 2035, leading forensic organizations will need to manage at least 6 priorities: analytical accuracy, automation, cybersecurity, data interpretation, court admissibility, and workforce development.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Polymerase Chain Reaction (PCR): Polymerase Chain Reaction (PCR) leads with approximately 26% market share because forensic DNA workflows rely on amplification to generate sufficient genetic material for analysis. PCR can increase targeted DNA regions through approximately 25-35 thermal cycles depending on assay design. Modern multiplex PCR kits simultaneously amplify multiple STR regions in one reaction, reducing sample consumption while increasing identification power. PCR remains central to Judicial and Law Enforcement, missing-person investigations, biological evidence analysis, and selected Pharmacogenetics workflows. The technology is expected to retain leadership through 2035 even as NGS adoption increases.

Capillary Electrophoresis: Capillary Electrophoresis accounts for approximately 20% market share and remains the established platform for STR fragment separation and forensic human identification. Modern genetic analyzers can examine multiple fluorescent dye channels and numerous loci from one amplified sample. The technology benefits from decades of laboratory validation, extensive population databases, established interpretation standards, and compatibility with national DNA databases. Capillary Electrophoresis will remain important through 2035 because forensic laboratories require continuity with millions of existing STR profiles even as NGS becomes more prominent.

Next-Generation Sequencing (NGS): Next-Generation Sequencing (NGS) represents approximately 17% market share and is one of the fastest-growing Product Types. NGS can analyze hundreds of genetic markers simultaneously and provide sequence-level information beyond conventional fragment-length measurement. Applications include degraded DNA, unidentified remains, complex kinship, ancestry-related investigation, mitochondrial DNA, and selected forensic research. Adoption is expanding as laboratories validate interpretation workflows and sequencing costs decline. The segment is expected to increase its market share substantially through 2035.

Rapid DNA Analysis: Rapid DNA Analysis accounts for approximately 13% market share and integrates extraction, amplification, separation, detection, and profile generation within automated systems. Current systems can produce selected DNA profiles in approximately 90 minutes with around 1 minute of hands-on operation. Rapid workflows are being evaluated for booking environments, crime laboratories, disaster victim identification, human remains, and selected evidence types. Recent workflow enhancements adding approximately 12 minutes of pre-extraction processing demonstrate continuing technical improvement.

Automated Liquid Handling Technology: Automated Liquid Handling Technology represents approximately 10% market share and is increasingly important for laboratories processing large DNA backlogs. Modern robotic platforms can purify as many as 96 samples in less than 90 minutes and can automate portions of extraction, quantification, normalization, and amplification plate setup. Automation reduces repetitive pipetting and provides consistent liquid volumes across large batches. Demand is expected to grow faster than traditional manual preparation because laboratory caseloads continue increasing.

Microarrays: Microarrays account for approximately 6% market share and support high-throughput analysis of genetic variants and selected biological signatures. Microarray platforms can interrogate thousands to hundreds of thousands of predefined markers, depending on array design. Although NGS is gaining share in many genomic workflows, microarrays remain useful where laboratories require standardized, predefined genetic information at predictable cost. Pharmacogenetics represents an important Application because microarrays can analyze multiple clinically relevant variants simultaneously.

Others: Others represents approximately 8% market share and includes complementary analytical technologies used across toxicology, spectroscopy, microscopy, imaging, biometric identification, trace evidence, and chemical examination. Modern forensic toxicology databases can include more than 9,000 compounds and over 13,000 accurate-mass MS/MS spectra across several thousand compounds. These technologies support identification of drugs, poisons, fibers, paints, explosives, unknown chemicals, and additional evidentiary materials beyond DNA.

By Applications

Pharmacogenetics: Pharmacogenetics represents approximately 20% market share and uses molecular technologies to examine how genetic variation influences drug metabolism and response. PCR, Microarrays, and Next-Generation Sequencing (NGS) are particularly relevant because individual assays can evaluate multiple genetic variants within one analytical workflow. Pharmacogenetic information can support toxicological interpretation when investigators need to understand unusual drug concentrations or metabolism. The Application is expected to expand through 2035 as genomic laboratory capabilities become more widely available.

Biodefense & Biosurveillance: Biodefense & Biosurveillance accounts for approximately 15% market share and uses molecular analysis to identify biological organisms, monitor threats, characterize genetic variation, and support incident investigation. PCR provides rapid targeted detection, while NGS offers broader sequencing when the biological agent is uncertain. Modern laboratories can process dozens or hundreds of samples per batch using automated preparation. Demand is influenced by national-security programs, public-health preparedness, border security, and biological incident response.

Judicial and Law Enforcement: Judicial and Law Enforcement leads with approximately 54% market share. Applications include criminal casework, offender databases, missing persons, sexual-assault evidence, human identification, disaster victim identification, toxicology, and crime-scene analysis. Major national DNA systems contain more than 25 million profiles and have supported hundreds of thousands of investigations. Judicial laboratories therefore create the largest demand for PCR, Capillary Electrophoresis, Rapid DNA Analysis, automated liquid handling, toxicology, and related forensic platforms.

Others: Others represents approximately 11% market share and includes private investigations, workplace testing, insurance-related analysis, academic research, archaeological identification, humanitarian work, and specialized laboratory services. Private laboratories can offer advanced analytical testing where public forensic organizations lack internal capability. Specialized laboratories may maintain hundreds or thousands of validated assays spanning toxicology, genetics, trace analysis, and chemical characterization. Outsourcing is expected to remain important for unusual or low-volume evidence types.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to lead the Forensic Technology Market with approximately 39% global share in 2026. The United States maintains one of the world's largest forensic DNA infrastructures, with more than 200 law-enforcement laboratories able to compare profiles through interconnected national systems. By late 2025, the National DNA Index included more than 19 million offender profiles, over 6 million arrestee profiles, and approximately 1.4 million forensic profiles.

Regional growth is supported by DNA backlog reduction, Rapid DNA Analysis, forensic toxicology, NGS, automated liquid handling, and laboratory modernization. Thermo Fisher Scientific, GE Healthcare, Agilent Technologies, Forensic Fluids Laboratories, NMS Labs, and NEOGEN CORPORATION provide supplied-company representation in the U.S. North America is estimated to grow approximately 13-14% annually through 2035 as laboratories replace older instruments and expand automated capacity.

Europe

Europe represents approximately 28% of global Forensic Technology Market demand and maintains sophisticated forensic laboratory networks across the U.K., Germany, France, the Netherlands, Scandinavia, Switzerland, and other countries. Eurofins Scientific in Luxembourg, Forensic Pathways in the U.K., and IDEMIA in France provide substantial supplied-company representation. Judicial and Law Enforcement is estimated to account for approximately 51% of regional demand.

European laboratory investment includes expansion of modern forensic facilities. A major forensic services operator completed an approximately 5,000-square-meter U.K. facility supporting DNA recovery, drug analysis, and elemental analysis. Europe is also adopting automated DNA processing and biometric identification while maintaining strict quality-management requirements. The region is projected to expand approximately 12-14% annually through 2035.

Asia-Pacific

Asia-Pacific is estimated to account for approximately 24% of global market demand and is projected to be the fastest-growing region at approximately 16.8% annually. China, Japan, India, South Korea, Australia, Singapore, and Southeast Asian countries are modernizing forensic laboratories and expanding genomic, toxicology, and biometric capabilities. HORIBA, Ltd. provides supplied-company representation from Japan.

Asia-Pacific growth is supported by population scale, expansion of national identification infrastructure, investment in modern policing, and rising demand for domestic laboratory capacity. Governments increasingly seek automated platforms capable of handling 96-sample batches rather than relying on manual workflows. NGS adoption is also increasing within advanced regional laboratories. By 2035, Asia-Pacific is expected to narrow the market-share gap with North America as laboratory modernization accelerates.

Middle East & Africa

Middle East & Africa accounts for approximately 4% of global Forensic Technology Market demand. Gulf countries, South Africa, and selected North African markets are investing in forensic genetics, toxicology, biometric identification, and security-related analytical systems. Judicial and Law Enforcement accounts for approximately 56% of regional demand, while Biodefense & Biosurveillance contributes around 19%.

The region is expected to grow approximately 13-15% annually through 2035. New laboratories increasingly adopt integrated systems rather than building workflows around older standalone equipment. Automated platforms capable of performing multiple DNA-processing stages can be attractive where specialist laboratory staff remain limited. Regional demand will depend on government investment, accreditation, training, cybersecurity, and long-term technical support.

List of Top Forensic Technology Companies

• Eurofins Scientific (Luxembourg)
• Forensic Pathways (U.K.)
• Thermo Fisher Scientific Inc. (U.S.)
• IDEMIA (France)
• GE Healthcare (U.S.)
• Agilent Technologies, Inc. (U.S.)
• HORIBA, Ltd. (Japan)
• Forensic Fluids Laboratories (U.S.)
• NMS Labs (U.S.)
• NEOGEN CORPORATION (U.S.)

Top 2 Companies Market Share

Thermo Fisher Scientific Inc.: Thermo Fisher Scientific Inc. is estimated to represent approximately 17-20% of competitive presence among the supplied companies, supported by extensive PCR, Capillary Electrophoresis, Rapid DNA Analysis, Next-Generation Sequencing, DNA quantification, and Automated Liquid Handling Technology portfolios. Its Rapid DNA platform can generate selected forensic DNA profiles in approximately 90 minutes with around 1 minute of hands-on time. Automated sample-preparation systems can purify up to 96 DNA samples in less than 90 minutes, allowing laboratories to substantially increase throughput. The company's combination of reagents, instruments, software, and validated workflows gives it strong positioning within Judicial and Law Enforcement applications.

Eurofins Scientific: Eurofins Scientific is estimated to account for approximately 13-16% of competitive presence among the supplied companies, supported by broad laboratory-service capabilities across forensic DNA, toxicology, drug testing, and specialized analytical services. Its U.K. forensic infrastructure includes an approximately 5,000-square-meter laboratory and office complex supporting DNA recovery, drug analysis, and elemental analysis. The facility complements additional forensic operations and provides space for future laboratory expansion. Eurofins' network-based service model is particularly relevant where law-enforcement organizations require outsourced testing to address backlog or access specialized methods.

Investment Analysis

Investment in the Forensic Technology Market is increasingly directed toward automated DNA processing, Next-Generation Sequencing, Rapid DNA Analysis, high-resolution toxicology, laboratory information management, and expanded forensic capacity. High-volume DNA systems must accommodate databases containing more than 25 million profiles and annual additions exceeding 1 million samples. This scale makes automated sample handling attractive because platforms can process up to 96 specimens in less than 90 minutes during selected workflow stages. Public-sector investment also remains important for backlog reduction, with government forensic and DNA programs historically funding thousands of projects. Capital expenditure is shifting toward integrated platforms capable of performing several analytical stages with reduced human intervention.

Laboratory expansion represents another significant investment area. New forensic facilities are being designed around larger evidence volumes, advanced ventilation, secure sample storage, automated extraction, mass spectrometry, and digital chain-of-custody systems. One recently completed forensic laboratory spans approximately 5,000 square meters and supports DNA recovery, drug analysis, and elemental testing in one location. Investment is also increasing in analytical databases because modern toxicology systems can screen thousands of compounds. Through 2035, strategic spending is expected to concentrate on approximately 6 areas: PCR modernization, NGS, Rapid DNA Analysis, automation, toxicology, and laboratory data infrastructure.

New Product Development

New Product Development in the Forensic Technology Market is focused on reducing processing time while extracting more information from limited evidence. Rapid DNA technology illustrates this trend because systems capable of approximately 90-minute profiling are being enhanced to work with increasingly difficult crime-scene evidence. During 2026, researchers demonstrated a approximately 12-minute pre-extraction process that improved DNA recovery before Rapid DNA analysis. Automated platforms are also consolidating purification, quantification, and amplification setup so laboratories can process as many as 96 samples in a single high-throughput workflow. These technologies reduce repetitive manual work while helping laboratories standardize evidence handling.

Advanced analytical development is simultaneously expanding forensic toxicology and genomic capabilities. Compact GC/MS systems are becoming more powerful, while forensic toxicology libraries can contain more than 2,800 targeted compounds and accurate-mass databases can exceed 9,000 compounds. Next-Generation Sequencing is enabling forensic scientists to move from a few dozen conventional markers toward hundreds of potential genetic targets. New DNA quantification products are also designed to evaluate both quantity and quality before downstream testing, reducing wasted sample and improving workflow selection. Through 2035, products will increasingly compete across at least 7 attributes: speed, sensitivity, automation, multiplexing, traceability, data interpretation, and evidence preservation.

Five Recent Developments

• February 2026: Rapid DNA research demonstrated a approximately 12-minute pre-extraction protocol that improved recovery from difficult evidence while supporting profiles generated through approximately 90-minute automated analysis.
• January 2026: High-throughput forensic DNA workflows increasingly incorporated automated platforms capable of purifying and preparing up to 96 samples in less than 90 minutes.
• May 2025: Agilent enhanced its compact 8850 Gas Chromatograph with mass-spectrometry connectivity, expanding a high-speed analytical platform applicable to forensic laboratory identification and quantification workflows.
• January 2025: Advanced forensic toxicology workflows incorporated a GC/MS/MS database containing approximately 1,800 MRM transitions for more than 170 toxicologically relevant compounds.
• July 2024: Eurofins completed an approximately 5,000-square-meter forensic laboratory facility in the U.K. supporting advanced DNA recovery, drug analysis, elemental analysis, and expanded forensic operations.

Report Coverage

The Forensic Technology Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Polymerase Chain Reaction (PCR), Capillary Electrophoresis, Next-Generation Sequencing (NGS), Rapid DNA Analysis, Automated Liquid Handling Technology, Microarrays, and Others. Estimated Product Type shares are approximately 26%, 20%, 17%, 13%, 10%, 6%, and 8%, respectively. Application coverage includes Pharmacogenetics at approximately 20%, Biodefense & Biosurveillance at 15%, Judicial and Law Enforcement at 54%, and Others at 11%. Current technical indicators include Rapid DNA results in approximately 90 minutes, automated 96-sample processing in less than 90 minutes, toxicology databases covering more than 2,800 compounds, and national DNA databases exceeding 25 million profiles.

Regional coverage includes North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa, with estimated market shares of approximately 39%, 28%, 24%, 5%, and 4%, respectively. Competitive coverage includes all 10 supplied companies: Eurofins Scientific, Forensic Pathways, Thermo Fisher Scientific Inc., IDEMIA, GE Healthcare, Agilent Technologies, Inc., HORIBA, Ltd., Forensic Fluids Laboratories, NMS Labs, and NEOGEN CORPORATION. The analysis evaluates DNA profiling, forensic toxicology, genetic sequencing, automation, biodefense, biometric identification, trace evidence, laboratory workflows, backlog reduction, and judicial applications. The report assesses how Rapid DNA Analysis, Next-Generation Sequencing, high-throughput automation, expanding DNA databases, advanced toxicology, and digital evidence-management infrastructure will shape the Forensic Technology Market through 2035.